Recommended

Lilly demonstrates alopecia areata promise in major study
Novartis bets $12bn on potential first-in-class RNA therapeutics
Process analytical tool could aid real-time monitoring in vaccine manufacturing
CPHI Pharma Awards 2025 winners announced
Drug delivery study offers potential “paradigm shift” in restenosis
Lilly AI supercomputer set to advance pharma manufacturing
FDA draft guidance to streamline biosimilar development
Novo Nordisk bids $6.5 billion for Metsera
news

COVID-19 vaccines to be monitored post-marketing by consortium in UK

0
SHARES

The ‘One Million Post-Authorisation Study’ has been established to monitor the safety and effectiveness of COVID-19 vaccines in real-life conditions. 

Patient receiving vaccine

A UK consortium has announced plans for a ‘One Million Post-Authorisation Study’ to monitor the safety and effectiveness of approved COVID-19 vaccines in real-life conditions. The consortium has been formed by the Drug Safety Research Unit (DSRU) in Southampton, led by Professor Saad Shakir, who will work with a range of scientists across the UK. 

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The One Million Post-Authorisation Study will conduct essential monitoring at the ‘post-marketing’ stage to ensure vaccines work and are safe as they should.

One million members of the public who receive a COVID-19 vaccine will be invited to take part. Those who agree will be contacted at set points after the vaccine to check on their health. The study is designed to respond frequently, so that any concerns regarding safety or efficacy can be detected and acted upon quickly. 

According to the team, during the current pandemic, COVID-19 vaccines are going through R&D with unprecedented speed, with development being reduced from 10-12 years to 12-18 months. Therefore, they say it is necessary to conduct post-marketing observational studies to monitor the safety and effectiveness of COVID-19 vaccines and that these studies report in real-time any safety or lack of effectiveness signals so that action can be taken in a timely way. The post-authorisation studies also fill any gaps in knowledge obtained from pre-marketing clinical trials.

Professor Shakir said: “It is well-known that a safe and effective vaccine is vital for protecting the public from COVID-19. The usual development process for a vaccine, including proving its safety and effectiveness, would normally take over a decade, but has been reduced to 12-18 months for COVID-19 vaccines. The methods of the One Million Study benefit from the structure of the National Health Service (NHS) and have been developed to allow near real-time reporting of safety and effectiveness signals, which will be crucial for monitoring newly-licensed COVID-19 vaccines. This is a vital part of ensuring that any vaccine can be safely deployed around the world.”

Share via
Share via